European Association for the Study of Diabetes

The latest news from the EASD Annual Meeting, with physician perspective, researcher interviews and clinician insight.

Meeting News Coverage

Men with type 1 diabetes controlled blood glucose better than women

September 25, 2013
Females with type 1 diabetes were more likely to have higher HbA1c than their male counterparts, data from 12 countries showed. In a poster presented…
Meeting News Coverage

Lixisenatide with basal insulin improved glycemic control

September 24, 2013
The addition of lixisenatide to basal insulin improved glycemic control, especially in patients with controlled fasting plasma glucose, a presenter…
Meeting News Coverage

CKD risk score predicted microalbuminuria in type 2 diabetes

August 20, 2013
A predefined chronic kidney disease risk score using proteomic measurements accurately predicted the development of persistent microalbuminuria…
Meeting News Coverage

CANVAS: Canagliflozin effective as add-on therapy in type 2 diabetes

October 10, 2012
Patients with type 2 diabetes who are at elevated risk for cardiovascular disease experienced significant reductions in blood glucose when using…
Meeting News Coverage

Empagliflozin lowered systolic BP, regardless of weight, HbA1c

Endocrine Today, November 2012
Patients with type 2 diabetes experienced significant reductions in systolic blood pressure after treatment with empagliflozin that were…
Meeting News Coverage

Diabetes increases death rate among U.K. youth

Endocrine Today, November 2012
Research presented at the 48th Annual Meeting of the European Association for the Study of Diabetes in Berlin demonstrates that women in the U.K…
Meeting News Coverage

President of EASD calls for improved device registration, monitoring in Europe

Endocrine Today, November 2012
European diabetes device regulation is in need of “radical change,” according to president of the European Association for the Study of …
Meeting News Coverage

Investigational DPP-IV inhibitor at various doses reduced HbA1c in type 2 diabetes

October 3, 2012
Phase 2b results have demonstrated that an investigational, once-weekly DPP-IV inhibitor significantly lowered HbA1c, compared with placebo, among…
Meeting News Coverage

Injection-free exenatide well tolerated, effective at higher doses

Endocrine Today, November 2012
As part of a 24-week phase 2 study to select a specific dosing regimen for a phase 3 clinical program, researchers found that higher doses of…
Meeting News Coverage

Four studies find linagliptin effective as monotherapy, add-on in adults with type 2 diabetes

October 2, 2012
Linagliptin administered alone or in combination with other diabetes medications, and as an add-on to basal insulin therapy, lowered HbA1c in…